Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regencell Bioscience HoldingsRGC -0.55%30 3-Year EBITDA Growth Rate is 20.60% as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 811 Drug Manufacturers companies, Regencell Bioscience Holdings ranks better than 69.3% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -29.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regencell Bioscience Holdings was 20.60% per year. The lowest was -141.00% per year. And the median was -57.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Regencell Bioscience Holdings 3-Year EBITDA Growth Rate Related Terms
RGC vs SUPN, BCRX, PBH: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.60% mean?
Regencell Bioscience Holdings (RGC) has a 3-Year EBITDA Growth Rate of 20.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regencell Bioscience Holdings and its competitors. According to the industry distribution chart, Regencell Bioscience Holdings ranks #249 out of 811 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Regencell Bioscience Holdings' 3-Year EBITDA Growth Rate too high?
Regencell Bioscience Holdings' current 3-Year EBITDA Growth Rate is 20.60%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Regencell Bioscience Holdings' value of 20.60% is 134.1% above this industry median. Based on the distribution chart, Regencell Bioscience Holdings ranks #249 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Regencell Bioscience Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' 3-Year EBITDA Growth Rate compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #249 out of 811 companies for 3-Year EBITDA Growth Rate. This puts Regencell Bioscience Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Regencell Bioscience Holdings' value of 20.60% is 134.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regencell Bioscience Holdings's current 3-Year EBITDA Growth Rate of 20.60% is 134.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current 3-Year EBITDA Growth Rate is 20.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current 3-Year EBITDA Growth Rate of 20.60%. The current 3-Year EBITDA Growth Rate is 20.60% and 134.1% above the Drug Manufacturers industry median of 8.80. Regencell Bioscience Holdings' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current 3-Year EBITDA Growth Rate is 20.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
30GF Score
Get the complete analysis for RGC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
